Evidence map›Paper›PMID 17784947›Full record

ArticleBMC infectious diseases2007

Comparative evaluation of (1, 3)-beta-D-glucan, mannan and anti-mannan antibodies, and Candida species-specific snPCR in patients with candidemia.

Fasahat F Alam, Abu S Mustafa, Zia U Khan

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC infectious diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 6 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 6 syntheses or guidelines pooled it, 128 citations in OpenAlex.

  1. Nucleic Acid Amplification Tests forPathogens (Basel, Switzerland) · 2026
    Pooled it
  2. Guideline
  3. Guideline
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Diagnostic performance of β-(1→3)-D-glucan, twoJournal of clinical microbiology · 2026
    Trial
  8. Trial
  9. Trial
  10. LAMP-Based Detection ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Article
  11. Extra-pulmonary invasive fungal infection in a post-heart transplant patient.Indian journal of thoracic and cardiovascular surgery · 2025
    Article
  12. Article
  13. Article
  14. Enablers ofCurrent medical mycology · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Performance of a new Candida anti-mannan IgM and IgG assays in the diagnosis of candidemia.Revista do Instituto de Medicina Tropical de Sao Paulo · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Fasahat F AlamDepartment of Microbiology, Faculty of Medicine, Kuwait University, Safat 13110, P, O, Box 24923, Kuwait. ujalaalam@hotmail.com
Abu S Mustafa
Zia U Khan
Kuwait University · KW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCandidemia is a major infectious complication of seriously immunocompromised patients. In the absence of specific signs and symptoms, there is a need to evolve an appropriate diagnostic approach. A number of methods based on the detection of Candida mannan, nucleic acid and (1,3)-beta- D- glucan (BDG) have been used with varying specificities and sensitivities. In this retrospective study, attention has been focused to evaluate the usefulness of two or more disease markers in the diagnosis of candidemia.

methodsDiagnostic usefulness of Platelia Candida Ag for the detection of mannan, Platelia Candida Ab for the detection of anti-mannan antibodies, Fungitell for the detection of BDG, and of a semi-nested PCR (snPCR) for the detection Candida species-specific DNA have been retrospectively evaluated using 32 sera from 27 patients with culture-proven candidemia, 51 sera from 39 patients with clinically suspected candidemia, sera of 10 women with C. albicans vaginitis, and sera of 16 healthy controls.

resultsUsing cut-off values recommended by the manufacturers, the sensitivity of the assays for candidemia patients were as follows: Candida snPCR 88%, BDG 47%, mannan 41%, anti-mannan antibodies 47%, respectively. snPCR detected 5 patients who had candidemia due to more than one Candida species. The sensitivities of the combined tests were as follows: Candida mannan and anti-mannan antibodies 75%, and Candida mannan and BDG 56%. Addition of snPCR data improved the sensitivity further to 88%, thus adding 10 sera that were negative by BDG and/or mannan. In clinically suspected, blood culture negative patients; the positivities of the tests were as follows: Candida DNA was positive in 53%, BDG in 29%, mannan in 16%, and anti-mannan antibodies in 29%. The combined detection of mannan and BDG, and mannan, BDG and Candida DNA enhanced the positivity to 36% and 54%, respectively. None of the sera from Candida vaginitis patients and healthy subjects were positive for Candida DNA and mannan.

conclusionThe observations made in this study reinforce the diagnostic value of snPCR in the sensitive and specific diagnosis of candidemia and detection of more than one Candida species in a given patient. Additionally, in the absence of a positive blood culture, snPCR detected Candida DNA in sera of more than half of the clinically suspected patients. While detection of BDG, mannan and anti-mannan antibodies singly or in combination could help enhancing sensitivity and eliminating false positive tests, a more extensive evaluation of these assays in sequentially collected serum samples is required to assess their value in the early diagnosis of candidemia.

Indexed as

Antibodies, FungalAntibody SpecificityAntigens, Fungalbeta-GlucansCandidaCandidiasisDNA, FungalFungemiaImmunoassayImmunoenzyme TechniquesMannansPolymerase Chain ReactionProteoglycansReagent Kits, DiagnosticRetrospective StudiesSensitivity and SpecificityAntibodies, FungalAntigens, Fungalbeta-GlucansDNA, FungalMannanspolysaccharide-KProteoglycansReagent Kits, Diagnostic

Identifiers

PMID17784947
PMCPMC2075513
OpenAlexW1974587901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.